Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance
• Veeva Systems (VEEV) Tops Q2 EPS by 13c; Offers Guidance